SRD5A2 and benign prostatic hyperplasia: In the present study, in vivo, and in vitro results indicated that AOS attenuated prostatic hypertrophy and pathological changes by inhibiting the proliferation of prostate epithelial cells, reducing the expression of testosterone-induced target genes SRD5A2, AR, and PSA, and decreasing the serum levels of testosterone and DHT.